Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 901–1,000 of 1,689
γ-secretases: from cell biology to therapeutic strategies
Bergmans, B. A., & De Strooper, B. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70332-1 · Cited by 170
Biogenesis and metabolism of Alzheimer’s disease Aβ amyloid peptides
Evin, G., & Weidemann, A. (2002) · Peptides · doi:10.1016/s0196-9781(02)00063-3 · Cited by 170
Breitner, J. C. S. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540320035011 · Cited by 177
Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease.
Gearing, M., Rebeck, G. W., Hyman, B. T., Tigges, J., & Mirra, S. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9382 · Cited by 179
Expression of Liver X Receptor Target Genes Decreases Cellular Amyloid β Peptide Secretion
Sun, Y., Yao, J., Kim, T.-W., & Tall, A. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300760200 · Cited by 179
Hunter, J. M., Kwan, J., Malek-Ahmadi, M., Maarouf, C. L., Kokjohn, T. A., Belden, C., Sabbagh, M. N., Beach, T. G., & Roher, A. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036893 · Cited by 178
Brenowitz, W. D., Nelson, P. T., Besser, L. M., Heller, K. B., & Kukull, W. A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.028 · Cited by 174
“APOE ε4 allele status, a strong risk factor for AD (Corder et al., 1993), is also associated with increased frequency of CAA (Attems et al., 2005, 2008; Nelson et al., 2013; Pfeifer et al., 2002; Ringman et al., 2014; Tanskanen et al., 2005; Thal et al., 2003).”
Louveau, A., Da Mesquita, S., & Kipnis, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.08.027 · Cited by 177
“Likewise, the rate of Ab transport by LRP1 is largely modulated by its ligands, Apo-E and a2-macroglobulin (Blacker et al., 1997; Corder et al., 1993; Liao et al., 1998).”
BackgroundSpecific Regional Transcription of Apolipoprotein E in Human Brain Neurons
Xu, P.-T., Gilbert, J. R., Qiu, H.-L., Ervin, J., Rothrock-Christian, T. R., Hulette, C., & Schmechel, D. E. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65305-9 · Cited by 176
Self-citationLee, C. Y. D., Tse, W., Smith, J. D., & Landreth, G. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.295451 · Cited by 178
G2D: a tool for mining genes associated with disease
Perez-Iratxeta, C., Wjst, M., Bork, P., & Andrade, M. A. (2005) · BMC Genetics · doi:10.1186/1471-2156-6-45 · Cited by 178
“Following the example, we type in the "PHENOTYPE BOX" OMIM id window, 104310, which is the OMIM id corresponding to another LOFAD, the AD2 that was linked to the gene APOE4 [10].”
MethodSchikowski, T., Vossoughi, M., Vierkötter, A., Schulte, T., Teichert, T., Sugiri, D., Fehsel, K., Tzivian, L., Bae, I.-S., Ranft, U., et al. (2015) · Environmental Research · doi:10.1016/j.envres.2015.06.009 · Cited by 171
Coordination of Lipid Metabolism in Membrane Biogenesis
Nohturfft, A., & Zhang, S. C. (2009) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.24.110707.175344 · Cited by 175
Shorter telomeres are associated with mortality in those with APOE ϵ4 and dementia
Honig, L. S., Schupf, N., Lee, J. H., Tang, M. X., & Mayeux, R. (2006) · Annals of Neurology · doi:10.1002/ana.20894 · Cited by 175
“The presence of an APOE ε4 allele has been associated with both mortality(20,22) and earlier onset of dementia.(23,33,34) In this study, the relation of telomere length to mortality was observed in those with, but not in those without, an ε4 allele.”
BackgroundGenetic dissection of Alzheimer disease, a heterogeneous disorder.
Schellenberg, G. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8552 · Cited by 177
Ji, Z.-S., Miranda, R. D., Newhouse, Y. M., Weisgraber, K. H., Huang, Y., & Mahley, R. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112109200 · Cited by 177
Role of apolipoprotein E in neurodegenerative diseases
Van Giau, V., Bagyinszky, E., An, S. S., & Kim, S. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84266 · Cited by 171
Precortical Phase of Alzheimer's Disease (AD)‐Related Tau Cytoskeletal Pathology
Stratmann, K., Heinsen, H., Korf, H., Del Turco, D., Ghebremedhin, E., Seidel, K., Bouzrou, M., Grinberg, L. T., Bohl, J., Wharton, S. B., et al. (2016) · Brain Pathology · doi:10.1111/bpa.12289 · Cited by 173
“The presence of the APOE ε4 allele is a well-established risk factor for the development of AD (24, 34).”
BackgroundPharmacogenetics in drug discovery and development: a translational perspective
Roses, A. D. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2593 · Cited by 174
Self-citationPolygenic risk of Alzheimer disease is associated with early- and late-life processes
Mormino, E. C., Sperling, R. A., Holmes, A. J., Buckner, R. L., De Jager, P. L., Smoller, J. W., Sabuncu, M. R., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002922 · Cited by 176
Doris, P. A. (2002) · Hypertension · doi:10.1161/hy0202.104087 · Cited by 179
Status of Risk Factors for Vascular Dementia
Skoog, I. (1998) · Neuroepidemiology · doi:10.1159/000026147 · Cited by 178
The burden of complex genetics in brain disorders
Uhl, G. R., & Grow, R. W. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.3.223 · Cited by 176
APOE ε2 is associated with milder clinical and pathological Alzheimer disease
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A., & Hyman, B. T. (2015) · Annals of Neurology · doi:10.1002/ana.24369 · Cited by 176
AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease
Rosenberg, J. B., Kaplitt, M. G., De, B. P., Chen, A., Flagiello, T., Salami, C., Pey, E., Zhao, L., Ricart Arbona, R. J., Monette, S., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.231 · Cited by 176
“5fold compared to APOE3 homozygotes), as well as an earlier age of onset for developing the disease (approximately 5 years for each APOE4 allele compared to APOE3 homozygotes).(6,9,10) Between 45% and 50% of AD patients carry at least one APOE4 allele compared to only 15% of age-matched healthy controls.”
BackgroundRisk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort
Breitner, J. C. S., Haneuse, S. J. P. A., Walker, R., Dublin, S., Crane, P. K., Gray, S. L., & Larson, E. B. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a18691 · Cited by 179
McDonagh, D. L., Mathew, J. P., White, W. D., Phillips-Bute, B., Laskowitz, D. T., Podgoreanu, M. V., & Newman, M. F. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181d31fd7 · Cited by 172
Lehtovirta, M., Laakso, M. P., Soininen, H., Helisalmi, S., Mannermaa, A., Helkala, E.-L., Partanen, K., Ryynänen, M., Vainio, P., Hartikainen, P., et al. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00014-a · Cited by 172
Alzheimer's disease: the lipid connection
Hartmann, T., Kuchenbecker, J., & Grimm, M. O. W. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04715.x · Cited by 175
Fitz, N. F., Cronican, A., Pham, T., Fogg, A., Fauq, A. H., Chapman, R., Lefterov, I., & Koldamova, R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1051-10.2010 · Cited by 175
Role of mitochondrial homeostasis and dynamics in Alzheimer's disease
Selfridge, J. E., E, L., Lu, J., & Swerdlow, R. H. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.057 · Cited by 175
The role of seladin‐1/DHCR24 in cholesterol biosynthesis, APP processing and Aβ generation in vivo
Crameri, A., Biondi, E., Kuehnle, K., Lütjohann, D., Thelen, K. M., Perga, S., Dotti, C. G., Nitsch, R. M., Ledesma, M. D., & Mohajeri, M. H. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7600938 · Cited by 170
“Thus, concentrated effort has been focused on the identification of modifying factors (Corder et al, 1993) and regulatory mechanisms of the proteases that control APP cleavage and are involved in Ab production, as well as on proteases with the capacity to degrade the peptide (Selkoe, 2001).”
BackgroundTrajectories of cognitive decline in Alzheimer's disease
Wilkosz, P. A., Seltman, H. J., Devlin, B., Weamer, E. A., Lopez, O. L., DeKosky, S. T., & Sweet, R. A. (2010) · International Psychogeriatrics · doi:10.1017/s1041610209991001 · Cited by 166
The ARIC-PET amyloid imaging study: Brain amyloid differences by age, race, sex, and APOE
Gottesman, R. F., Schneider, A. L. C., Zhou, Y., Chen, X., Green, E., Gupta, N., Knopman, D. S., Mintz, A., Rahmim, A., Sharrett, A. R., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002914 · Cited by 172
Cherrie, M. P. C., Shortt, N. K., Mitchell, R. J., Taylor, A. M., Redmond, P., Thompson, C. W., Starr, J. M., Deary, I. J., & Pearce, J. R. (2018) · Social Science & Medicine · doi:10.1016/j.socscimed.2017.10.038 · Cited by 166
“The presence of APOE e4 alleles is mainly associated with Alzheimer's dementia (Corder et al., 1993) and women experience cardiovascular health problems 7-10 years later than men (Maas and Appelman, 2010).”
Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer's disease?
Celsis, P. (2000) · Annals of Medicine · doi:10.3109/07853890008995904 · Cited by 161
Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174
“…binding clathrin assembly protein (PICALM, chromosome 11) and complement component (3b/4b) receptor 1 (CR1, chromosome 1), among others (Corder et al., 1993; Farrer et al., 1997; Marzolo and Bu, 2009; Bu, 2009; Harold et al., 2009; Lambert et al., 2009; Seshadri et al., 2010; Jun et…”
BackgroundPU.1 regulates Alzheimer’s disease-associated genes in primary human microglia
Rustenhoven, J., Smith, A. M., Smyth, L. C., Jansson, D., Scotter, E. L., Swanson, M. E. V., Aalderink, M., Coppieters, N., Narayan, P., Handley, R., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0277-1 · Cited by 155
Brain network local interconnectivity loss in aging APOE-4 allele carriers
Brown, J. A., Terashima, K. H., Burggren, A. C., Ercoli, L. M., Miller, K. J., Small, G. W., & Bookheimer, S. Y. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109038108 · Cited by 169
“Individuals in this group are three to four times more likely to develop AD and have a younger mean age at onset than APOE-4 noncarriers (2).”
BackgroundSelf-citationLongitudinal change in hippocampal volume as a function of apolipoprotein E genotype
Moffat, S. D., Szekely, C. A., Zonderman, A. B., Kabani, N. J., & Resnick, S. M. (2000) · Neurology · doi:10.1212/wnl.55.1.134 · Cited by 169
Mechanism of Cerebral β-Amyloid Angiopathy: Murine and Cellular Models
Herzig, M. C., Nostrand, W. E., & Jucker, M. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2006.tb00560.x · Cited by 169
“The apolipoprotein E (ApoE) ε4 allele is a known genetic risk factor for developing both AD (26, 165, 191) and Aβ-CAA (70, 144, 178).”
BackgroundFamilial risk for Alzheimer's disease alters fMRI activation patterns
Bassett, S. S., Yousem, D. M., Cristinzio, C., Kusevic, I., Yassa, M. A., Caffo, B. S., & Zeger, S. L. (2006) · Brain · doi:10.1093/brain/awl089 · Cited by 171
“While earlier studies reported an association between the e4 allele and risk for Alzheimer's disease in a dose-dependent manner (Corder et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993; Rebeck et al., 1993; Mullan et al., 1996), more recent reports make it clear that while the e4…”
ResultCodeposition of Cystatin C with Amyloid-β Protein in the Brain of Alzheimer Disease Patients
Levy, E., Sastre, M., Kumar, A., Gallo, G., Piccardo, P., Ghetti, B., & Tagliavini, F. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.1.94 · Cited by 170
“This finding is in agreement with APOEe4 being highly associated with late-onset familial and sporadic AD (25, 26).”
ResultGender, cognitive decline, and risk of AD in older persons
Barnes, L. L., Wilson, R. S., Schneider, J. A., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2003) · Neurology · doi:10.1212/01.wnl.0000065892.67099.2a · Cited by 173
Huang, J. Y., & Bargh, J. A. (2014) · Behavioral and Brain Sciences · doi:10.1017/s0140525x13000290 · Cited by 155
Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization
Arendt, T. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00516-9 · Cited by 169
“It is the objective of the present paper to summarize evidence that it might be the disturbance of the structural brain self-organization which, based on both genetic and epigenetic information, constantly ªcreatesº and ªrecreatesº the brain throughout life, that is the defect that underlies AD.”
BackgroundYamazaki, Y., Painter, M. M., Bu, G., & Kanekiyo, T. (2016) · CNS Drugs · doi:10.1007/s40263-016-0361-4 · Cited by 164
“Of note, the frequency of APOE e4 allele is dramatically increased to 40–65 % in patients with AD [14, 16].”
BackgroundTherapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease
Williams, T., Borchelt, D. R., & Chakrabarty, P. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0358-9 · Cited by 171
Pathogenic Mechanisms of Alzheimer's Disease Analyzed in the APP23 Transgenic Mouse Model
STURCHLER‐PIERRAT, C., & STAUFENBIEL, M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06915.x · Cited by 168
Polygenic Risk Scores in Clinical Psychology: Bridging Genomic Risk to Individual Differences
Bogdan, R., Baranger, D. A. A., & Agrawal, A. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084847 · Cited by 163
“We now know that, with few exceptions [e.g., APOE, rs429358 and rs7412 haplotypes and Alzheimer’s Disease (Corder et al., 1993)], individual common variants are associated with small effects [e.g., odds ratios 1.1 (Schizophrenia Working Group of the Psychiatric Genomics, 2014)].”
InfluentialShared polygenic risk and causal inferences in amyotrophic lateral sclerosis
Bandres‐Ciga, S., Noyce, A. J., Hemani, G., Nicolas, A., Calvo, A., Mora, G., The ITALSGEN Consortium, The International ALS Genomics Consortium, Tienari, P. J., Stone, D. J., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25431 · Cited by 162
“The identification of the cholesterol transport protein, apolipoprotein E, as a major genetic risk factor for Alzheimer’s disease is also consistent with a role for cholesterol in the pathogenesis of neurodegenerative disease.(41,42) Despite this, the molecular mechanisms by which altered lipid metabolism leads to neu…”
BackgroundDevelopment of small molecule probes for the Beta-amyloid protein of Alzheimer's Disease
Klunk, W. E., Debnath, M. L., & Pettegrew, J. W. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90050-7 · Cited by 171
Louhija, J., Miettinen, H. E., Kontula, K., Tikkanen, M. J., Miettinen, T. A., & Tilvis, R. S. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.7.1084 · Cited by 172
Freitas, C., Mondragón-Llorca, H., & Pascual-Leone, A. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2011.04.001 · Cited by 161
“Apolipoprotein E (APOE) and its ε4 allele are thought to raise the risk of AD (Corder et al., 1993) in a dose-dependent manner (Bertram et al., 2007), and may also influence brain responses to TMS measures.”
BackgroundBrain amyloid and cognition in Lewy body diseases
Gomperts, S. N., Locascio, J. J., Marquie, M., Santarlasci, A. L., Rentz, D. M., Maye, J., Johnson, K. A., & Growdon, J. H. (2012) · Movement Disorders · doi:10.1002/mds.25048 · Cited by 168
Asymptomatic Cerebral Small Vessel Disease: Insights from Population-Based Studies
Das, A. S., Regenhardt, R. W., Vernooij, M. W., Blacker, D., Charidimou, A., & Viswanathan, A. (2019) · Journal of Stroke · doi:10.5853/jos.2018.03608 · Cited by 161
Presence of oestrogen receptor type beta in human retina
Munaut, C. (2001) · British Journal of Ophthalmology · doi:10.1136/bjo.85.7.877 · Cited by 168
Horsburgh, K., McCarron, M. O., White, F., & Nicoll, J. A. R. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00097-x · Cited by 170
Okuizumi, K., Onodera, O., Namba, Y., Ikeda, K., Yamamoto, T., Seki, K., Ueki, A., Nanko, S., Tanaka, H., Takahashi, H., et al. (1995) · Nature Genetics · doi:10.1038/ng1095-207 · Cited by 172
Kemp, A. H., Gordon, E., Rush, A. J., & Williams, L. M. (2008) · CNS Spectrums · doi:10.1017/s1092852900017120 · Cited by 170
Bien-Ly, N., Gillespie, A. K., Walker, D., Yoon, S. Y., & Huang, Y. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0033-12.2012 · Cited by 170
“Apolipoprotein E4 (apoE4) is a major genetic risk factor for Alzheimer’s disease (AD) (Corder et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993a).”
BackgroundAβ-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease
Huang, Y. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.04.004 · Cited by 170
Neuroplasticity in Alzheimer's disease
Teter, B., & Ashford, J. W. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10441 · Cited by 170
“menopausal women (Corder et al., 1993; Poirier et al., 1993b; Farrer et al., 1995, 1997; Schneider and Farlow, 1997; Yaffe et al., 1997, 2000; Bretsky et al., 1999).”
BackgroundSchiepers, O. J. G., Harris, S. E., Gow, A. J., Pattie, A., Brett, C. E., Starr, J. M., & Deary, I. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2010.137 · Cited by 159
Genetics of Alzheimer's Disease
Guerreiro, R., & Hardy, J. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0295-9 · Cited by 155
“In general, it seems that each 4 allele shifts the risk curve for developing AD forward by 5 years, and that each 2 allele shifts the risk curve backwards by a similar amount, relative to 3 homozygotes [58,59].”
BackgroundDuchek, J. M., Balota, D. A., Tse, C.-S., Holtzman, D. M., Fagan, A. M., & Goate, A. M. (2009) · Neuropsychology · doi:10.1037/a0016583 · Cited by 161
“Of course, the presence of the ε4 allele is a well-established risk factor for DAT (e.g., Blacker, 1997; Corder et al., 1993; Henderson et al., 1995).”
Sleep Duration and Subsequent Cortical Thinning in Cognitively Normal Older Adults
Spira, A. P., Gonzalez, C. E., Venkatraman, V. K., Wu, M. N., Pacheco, J., Simonsick, E. M., Ferrucci, L., & Resnick, S. M. (2016) · Sleep · doi:10.5665/sleep.5768 · Cited by 158
Berendsen, A. A. M., Kang, J. H., van de Rest, O., Feskens, E. J. M., de Groot, L. C. P. G. M., & Grodstein, F. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.11.026 · Cited by 165
Han, J., Chitu, V., Stanley, E. R., Wszolek, Z. K., Karrenbauer, V. D., & Harris, R. A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04225-1 · Cited by 161
Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer’s disease
van Olst, L., Simonton, B., Edwards, A. J., Forsyth, A. V., Boles, J. S., Jamshidi, P., Watson, T. H., Shepard, N., Krainc, T., Argue, B. M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03574-1 · Cited by 186
“Both genes are established AD risk factors 19–22 and are associated with the microglial response to Aβ 23–26 .”
Syme, C. D., & Viles, J. H. (2006) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.09.012 · Cited by 167
Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits
Streit, W. J., & Sparks, D. L. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050097 · Cited by 168
“The increased occurrence of both diseases has been linked to presence of the apolipoprotein E type 4 allele [ 2 , 3] and to elevated levels of total serum cholesterol [4, 5]. Senile plaques occur with similar frequency in nondemented individuals with HD and in patients with AD [6].”
BackgroundBrain Parenchymal and Microvascular Amyloid in Alzheimer's Disease
Vinters, H. V., Wang, Z. Z., & Secor, D. L. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00799.x · Cited by 171
Nathan, B. P., Jiang, Y., Wong, G. K., Shen, F., Brewer, G. J., & Struble, R. G. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03367-4 · Cited by 169
Love, S., Chalmers, K. A., Ince, P. G., Esiri, M. M., Attems, J., Jellinger, K., Yamada, M., McCarron, M., Minett, T., Fiona, M., et al. (2014) · PubMed · doi:10.25405/ncl.34306728 · Cited by 168
APOE modifies the association between Aβ load and cognition in cognitively normal older adults
Kantarci, K., Lowe, V., Przybelski, S. A., Weigand, S. D., Senjem, M. L., Ivnik, R. J., Preboske, G. M., Roberts, R., Geda, Y. E., Boeve, B. F., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31824365ab · Cited by 159
Mutter, J., Curth, A., Naumann, J., Deth, R., & Walach, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100705 · Cited by 162
“Apolipoprotein E (ApoE) genotype is a consistent risk factor [41–46], and the ε4 genotype confers up to a 15-fold risk relative to the ε3 genotype [47, 48], which is the most widely distributed, whereas the ε2 genotype is protective.”
Johnson, E. L., Krauss, G. L., Lee, A. K., Schneider, A. L. C., Dearborn, J. L., Kucharska-Newton, A. M., Huang, J., Alonso, A., & Gottesman, R. F. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1935 · Cited by 163
Biel, D., Brendel, M., Rubinski, A., Buerger, K., Janowitz, D., Dichgans, M., Franzmeier, N., & (ADNI), F. T. A. D. N. I. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00880-x · Cited by 152
Kamino, K., Nagasaka, K., Imagawa, M., Yamamoto, H., Yoneda, H., Ueki, A., Kitamura, S., Namekata, K., Miki, T., & Ohta, S. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2923 · Cited by 173
Steffens, D. C., Plassman, B. L., Helms, M. J., Welsh-Bohmer, K. A., Saunders, A. M., & Breitner, J. C. S. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00247-8 · Cited by 169
Self-citationThe emerging role of glutathione in Alzheimer’s disease
Saharan, S., & Mandal, P. K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132483 · Cited by 168
“Postmortem analyses of AD brains containing the 4 allele of apolipoprotein E (ApoE) gene, an allele associated with earlier and more severe expression of AD pathology [42, 43], has shown that the extent of GSH reduction in AD is dependent on the presence and the number of ApoE 4 alleles, with GSH levels being the lowe…”
BackgroundBroersen, K., Rousseau, F., & Schymkowitz, J. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt36 · Cited by 168
“An interesting link with regard to this is the established fact that the ε4 allele of the gene encoding apolipoprotein, a cholesterol-carrying protein, has been defi ned as the major risk factor for AD, while the ε2 allele is protective [63,64].”
BackgroundUpdate on the Pharmacological Treatment of Alzheimers Disease
Massoud, F., & Gauthier, S. (2010) · Current Neuropharmacology · doi:10.2174/157015910790909520 · Cited by 163
“It will introduce future therapeutic options currently under study.”
BackgroundAPOE and cholesterol homeostasis in Alzheimer's disease
Leduc, V., Jasmin-Bélanger, S., & Poirier, J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.008 · Cited by 160
Lipopolysaccharide-Induced Memory Impairment in Rats: a Model of Alzheimer’s Disease
ZAKARIA, R., WAN YAACOB, W. M. H., OTHMAN, Z., LONG, I., AHMAD, A. H., & AL-RAHBI, B. (2017) · Physiological Research · doi:10.33549/physiolres.933480 · Cited by 167
“Inheritance of the apolipoprotein E type 4 allele (ApoE4) may also increase the risk of developing sporadic LOAD, though ApoE4 alone is neither necessary nor sufficient to cause AD (Corder et al. 1993, Strittmatter et al. 1993, Rossor et al. 1996, Sadigh-Eteghad et al. 2012).”
BackgroundNeuroimmune Connections in Aging and Neurodegenerative Diseases
Scheiblich, H., Trombly, M., Ramirez, A., & Heneka, M. T. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.02.002 · Cited by 166
Dá Mesquita, S., Ferreira, A. C., Sousa, J. C., Correia-Neves, M., Sousa, N., & Marques, F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.014 · Cited by 166
Cupples, L. A., Farrer, L. A., De Sadovnick, A. S., Relkin, N., Whitehouse, P., & Green, R. C. (2004) · Genetics in Medicine · doi:10.1097/01.gim.0000132679.92238.58 · Cited by 166
Head Injury and Risk of Alzheimer's Disease by Apolipoprotein E Genotype
O'Meara, E. S., Kukull, W. A., Sheppard, L., Bowen, J. D., McCormick, W. C., Teri, L., Pfanschmidt, M., Thompson, J. D., Schellenberg, G. D., & Larson, E. B. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009290 · Cited by 165
“APOE genotype was strongly associated with Alzheimer's disease in several recent studies (29-41).”
BackgroundCortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics
Maetzler, W., Liepelt, I., Reimold, M., Reischl, G., Solbach, C., Becker, C., Schulte, C., Leyhe, T., Keller, S., Melms, A., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.12.008 · Cited by 165
Conte, V., Uryu, K., Fujimoto, S., Yao, Y., Rokach, J., Longhi, L., Trojanowski, J. Q., Lee, V. M., McIntosh, T. K., & Praticò, D. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02560.x · Cited by 164
“While apolipoprotein E e4 allele is the best-documented genetic risk factor for SAD (Corder et al. 1993; Saunders et al. 1993; Strittmatter et al. 1993), traumatic brain injury (TBI) represents the most robust environmental AD risk factor (Schofield et al. 1997; Nemetz et al. 1999; Plassman et al. 2000; Jellinger et a…”
BackgroundInfluentialMicroglial Activation in Alzheimer Disease: Association with APOE Genotype
Egensperger, R., Kösel, S., von Eitzen, U., & Graeber, M. B. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00166.x · Cited by 164
“It confers an increased risk of expressing the disease and is associated with a younger mean age of onset as well as modification of the neuropathological phenotype in a dosedependent manner ( 8 , 48, 52, 53, 58).”
BackgroundCrean, S., Ward, A., Mercaldi, C. J., Collins, J. M., Cook, M. N., Baker, N. L., & Arrighi, H. M. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000321984 · Cited by 163
Seshadri, S. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540350068018 · Cited by 163
Chen, H.-K., Liu, Z., Meyer-Franke, A., Brodbeck, J., Miranda, R. D., McGuire, J. G., Pleiss, M. A., Ji, Z.-S., Balestra, M. E., Walker, D. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276162 · Cited by 163
Brain cholesterol in normal and pathological aging
Martin, M., Dotti, C. G., & Ledesma, M. D. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.03.011 · Cited by 162
Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging
Jagust, W. J., Landau, S. M., & Initiative, F. T. A. D. N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3266-12.2012 · Cited by 162
“…metabolism and greater activation in the brains of young ApoE4 carriers performing cognitive tasks (Reiman et al., 2004; Filippini et al., 2009; Dennis et al., 2010; Filippini et al., 2011), these findings raise the possibility that resting metabolic dysfunction due to either ApoE4-related…”
BackgroundSoininen, H., Kosunen, O., Helisalmi, S., Mannermaa, A., Paljärvi, L., Talasniemi, S., Ryynänen, M., & Riekkinen, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11343-6 · Cited by 162
Hu, J., Liu, C.-C., Chen, X.-F., Zhang, Y.-W., Xu, H., & Bu, G. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0001-3 · Cited by 161
“gene is the strongest genetic risk factor for late-onset AD (LOAD), whereas the ε2 allele is protective [2-6].”
Background
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.